Validated Immunoassays to Accelerate Therapeutic Genome Editing INDs NIH U01AI191209May 22, 2025 - Apr 30, 2028 Role: Co-Principal Investigator |
Optimal T-cell support for HIV neutralizing antibody induction to fusion peptide-inclusive regimens (Opti-FliP) NIH P01AI181044Dec 17, 2024 - Nov 30, 2029 Role: Principal Investigator |
Prevention of CMV infection with a viral IL-10 neutralizing antibody NIH R21AI188878Nov 18, 2024 - Oct 31, 2026 Role: Principal Investigator |
BD FACSymphony S6 NIH S10OD036449Sep 1, 2024 - Aug 31, 2025 Role: Principal Investigator |
Understanding reservoir effects and curative potential of a CD3/CCR5 bispecific antibody in infant macaques NIH R01AI184418Aug 6, 2024 - Jul 31, 2029 Role: Principal Investigator |
Enhancing Rigor and Reproducibility of Translational Nonhuman Primate Models for Genetic and Regenerative Therapies NIH R01OD036239Jul 1, 2024 - Jun 30, 2029 Role: Co-Principal Investigator |
A Phase 1/2a, randomized study of a Tfh-targeting genetic vaccine adjuvant designed to induce broad, durable immune responses NIH U01AI172800May 7, 2024 - Apr 30, 2029 Role: Co-Principal Investigator |
Impact of Maternal Inflammation and Cell Trafficking on Fetal Immune Ontogeny NIH R01HD107737May 6, 2024 - Feb 28, 2029 Role: Co-Principal Investigator |
Center for Somatic Cell Genome Editing in Nonhuman Primates NIH U42OD035737Sep 1, 2023 - Aug 31, 2028 Role: Co-Principal Investigator |
Multi-omic understanding of the transformed host T-cell response to HIV following therapeutic vaccination NIH P01AI178375May 22, 2023 - May 31, 2028 Role: Principal Investigator |
Genetic adjuvants to elicit neutralizing antibodies against HIV NIH R43MH133246Feb 6, 2023 - Jan 31, 2025 Role: Co-Principal Investigator |
CCR5 immunotoxins as components of HIV cure regimens NIH R41AI165350Jul 13, 2022 - Jun 30, 2024 Role: Principal Investigator |
Memory-promoting Ad vaccine for long-lived protection against SARS-CoV-2 NIH R41AI157626Jan 1, 2021 - Jul 31, 2021 Role: Principal Investigator |
Nucleic acid-based formulation of cytomegalovirus-vectored HIV vaccines NIH R41AI150232Apr 7, 2020 - Oct 31, 2021 Role: Principal Investigator |
Vaccination with self-launching RhCMV/SIV DNA vaccine vectors NIH R21AI150553Mar 10, 2020 - Feb 28, 2022 Role: Principal Investigator |
Effective CMV-based SIV vaccine regimens for newborn infants via IL-10 modulation NIH R01AI150554Dec 1, 2019 - Nov 30, 2024 Role: Principal Investigator |
Nonhuman Primate Testing Center for Evaluation of Somatic Cell Genome Editing Tools NIH U42OD027094Apr 15, 2019 - Mar 31, 2025 Role: Co-Principal Investigator |
Improved RhCMV/SIV vaccine efficacy via IL-10 pathway modulation NIH R01AI143554Sep 24, 2018 - Aug 31, 2023 Role: Principal Investigator |
Role of reservoir composition and T cell immunity in HIV rebound kinetics NIH P01AI131568Jul 19, 2017 - Jun 30, 2022 Role: Principal Investigator |
Congenital Zika Syndrome and Postnatal Outcomes in Nonhuman Primates NIH R21NS103658Jun 15, 2017 - May 31, 2019 Role: Co-Principal Investigator |
Short and long-term effects of infant microbiota on (RhCMV) SIV vaccine efficacy NIH R56AI120737Jul 1, 2016 - Jun 30, 2018 Role: Principal Investigator |
Reservoir depletion and anti-retroviral therapy for infant functional cure NIH R01AI118451Jun 1, 2015 - May 31, 2020 Role: Principal Investigator |
Effective lethal agents for CCR5+ expressing cells NIH R21AI116230Sep 1, 2014 - Aug 31, 2018 Role: Principal Investigator |
Regulatory T cell influence on infant and adult immune responses to HIV NIH K23AI081540Feb 1, 2009 - Jan 31, 2014 Role: Principal Investigator |
Impact of T-regulatory cells on SIV disease progression NIH F32AI067088Nov 1, 2005 - Oct 31, 2008 Role: Principal Investigator |